RSS | Login | Register

FORTEO

Compare to Similar Drugs | Add to Clipboard | View Clipboard | Print | Email

Close [X]

Compare FORTEO to:

Generic Name for FORTEO

Teriparatide (recombinant) 250micrograms/mL; soln for SC inj; contains m-cresol.

Legal Classification:

Pharmacological Class for FORTEO

Hormone (human parathyroid hormone, recombinant).

Manufacturer of FORTEO

Lilly, Eli and Company

Indications for FORTEO

Postmenopausal osteoporosis in women who are at high risk for fracture. To increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture. Treatment of men and women with osteoporosis associated with sustained glucocorticoid therapy at high risk for fracture (see literature).

Adult dose for FORTEO

20 micrograms SC once daily into thigh or abdominal wall; may treat for up to 2 years.

Children's dosing for FORTEO

Not recommended.

Warnings/Precautions for FORTEO

Increased baseline risk for osteosarcoma (eg, Paget's disease of bone, unexplained increased alkaline phosphatase, open epiphyses, prior skeletal radiation therapy), bone metastases, history of skeletal malignancies, metabolic bone disease, hypercalcemia or risk thereof (eg, hyperparathyroidism): not recommended. Urolithiasis. Hypercalciuria. Hepatic, renal, or cardiac disease. Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions for FORTEO

Caution with digoxin (teriparatide-induced hypercalcemia increases risk of toxicity).

Adverse Reactions for FORTEO

Arthralgia, pain, nausea; transient orthostatic hypotension, hypercalcemia, hyperuricemia, inj site reactions.

How is FORTEO supplied?

Multidose Pen (2.4mL, 3mL)—1

Related Disease:

Bone disorders

Osteoporosis~bone metabolism

Phase 3 study of oral calcitonin for the treatment of postmenopausal osteoporosis

July 23, 2010

Tarsa Therapeutics announced completion of patient enrollment in its Phase 3 study of oral calcitonin for the treatment of postmenopausal osteoporosis.

Prolia approved for postmenopausal osteoporosis

June 02, 2010

The FDA has approved Prolia (denosumab, from Amgen) for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.

FDA launches "Bad Ad Program" to detect misleading drug ads

May 11, 2010

The FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) has launched the Bad Ad Program, designed to educate healthcare providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading.

FDA reviews atypical subtrochanteric femur fractures risk with oral bisphosphonates

March 11, 2010

The FDA has notified healthcare professionals and patients that at this point, the data that have been reviewed have not shown a clear connection between bisphosphonate use and a risk of atypical subtrochanteric femur fractures.

Xiaflex available for Dupuytren's contracture

March 08, 2010

BioSpecifics Technologies and Auxilium Pharmaceuticals announced the availability of Xiaflex (collagenase clostridium histolyticum) for the treatment of adult Dupuytren's contracture patients with a palpable cord.